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Aim
To assess the safety and immunogenicity of the bivalent
HPV vaccine (Cervarix) in patients with Juvenile Idio-
pathic Arthritis (JIA), Systemic Lupus Erythematosus
(SLE) and Juvenile Dermatomyositis (JDM).
Methods
A prospective controlled observational trial was initiated
in female patients and healthy controls aged 12-18
years. Patients and controls were vaccinated (0, 1, and 6
months) and followed for 12 months. HPV16 and 18-
specific antibody concentrations were measured using a
fluorescent microspheres-based multiplex immuno-assay
after 12 months. Adverse events (AE’s) 2 weeks after
each vaccination were systematically documented in dia-
ries. In patients, medication use was monitored and dis-
ease activity was measured by the Juvenile Arthritis
Disease Activity Score of 27 joints (JADAS-27), SLE Dis-
ease Activity Index, or the Childhood Myositis Assess-
ment Scale.
Results
58 patients (45 JIA, 8 SLE, 5 JDM) and 51 healthy con-
trols are currently included, patients are still being
enrolled. The percentage of patients responding to vac-
cination (response rate) was similar in patients and con-
trols. However, HPV16 antibodies were lower in JIA
(5119 LU/ml, p=0.037), SLE (1461 LU/ml, p=0.002) and
JDM patients (3233 LU/ml, p=0.262) compared with
healthy controls (8799 LU/ml). HPV18 antibodies were
similar in JIA patients and controls (2764 LU/ml versus
2522 LU/ml, p=0.732); SLE (730 LU/ml, p=0.030) and
JDM patients (1147 LU/ml, p=0.384) showed markedly
lower antibody levels. MTX-use did not lower vaccine
responses.
The median JADAS-27 did change considerably
between visits (1.9-2.5), but JADAS-27 was significantly
elevated at 7 months (p=0.001) due to one outlier. SLE
and JDM disease activity remained similar. AE’sw e r e
similar in patients and controls.
Conclusion
Cervarix was safe in girls with rheumatic diseases. The
response rates were similar in patients and healthy con-
trols, whereas antibody concentrations were markedly
lower in SLE and JDM patients.
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